Study Design and Rationale of VALOR-HCM: Evaluation of Mavacamten in Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy who are Eligible for Septal Reduction Therapy

Publication date: Available online 24 May 2021Source: American Heart JournalAuthor(s): Milind Y Desai, Kathy Wolski, Anjali Owens, Srihari S Naidu, Jeffrey B Geske, Nicholas G Smedira, Hartzell Schaff, Kathy Lampl, Ellen McErlean, Christina Sewell, David Zhang, Jay M Edelberg, Amy J Sehnert, Steven E Nissen
Source: American Heart Journal - Category: Cardiology Source Type: research